M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments Pharmaceutical Business ReviewThese conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation.Immunology & InflammationRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) Pharmaceutical Business Review These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Immunology & Inflammation Read full story Post navigation Previous: Replimune rebounds to win FDA approval of melanoma drugNext: Intellia finds genetic suspect for liver safety signals with ATTR gene therapy Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026